Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G M Marx

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
Elevated alpha-foetoprotein and hepatic metastases--it's not always what it seems!G M Marx, A Boyce, D Goldstein
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 13, 2003
Pseudomyxoma peritonei: the 'controversial' diseaseE Galani, G M Marx, C B Steer, et al.
Internal Medicine Journal|November 17, 2009
Cancer in older people: a tale of two disciplinesC B Steer, G M Marx, N Singhal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patientsG M Marx, G M Blake, E Galani, et al.
Journal of Neuro-Oncology|January 5, 2002
Phase II study of thalidomide in the treatment of recurrent glioblastoma multiformeG M Marx, N Pavlakis, S McCowatt, et al.
Gynecologic Oncology|April 29, 2006
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First StudyC B Steer, K Chrystal, K A Cheong, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
Asia-Pacific Journal of Clinical Oncology|October 2, 2018
The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailableL Chin-Lenn, R H De Boer, E Segelov, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
Elevated alpha-foetoprotein and hepatic metastases--it's not always what it seems!G M Marx, A Boyce, D Goldstein
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 13, 2003
Pseudomyxoma peritonei: the 'controversial' diseaseE Galani, G M Marx, C B Steer, et al.
Internal Medicine Journal|November 17, 2009
Cancer in older people: a tale of two disciplinesC B Steer, G M Marx, N Singhal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patientsG M Marx, G M Blake, E Galani, et al.
Journal of Neuro-Oncology|January 5, 2002
Phase II study of thalidomide in the treatment of recurrent glioblastoma multiformeG M Marx, N Pavlakis, S McCowatt, et al.
Gynecologic Oncology|April 29, 2006
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First StudyC B Steer, K Chrystal, K A Cheong, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
Asia-Pacific Journal of Clinical Oncology|October 2, 2018
The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailableL Chin-Lenn, R H De Boer, E Segelov, et al.
Pageof 1